Benitec Biopharma Inc. (BNTC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. on May 29, 2026, covering events that occurred on May 22, 2026. The filing addresses changes to the composition of the Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of Director: David Friedman was appointed to the Board of Directors effective May 22, 2026, as a Class III member with a term expiring at the 2028 annual meeting.
- Compensatory Arrangement: Mr. Friedman was granted options to purchase 35,000 shares of common stock under the 2020 Equity and Incentive Compensation Plan. The grant date is May 26, 2026, with an exercise price equal to the closing price on that date. The options vest in full on the earlier of the next annual meeting or the first anniversary of the grant date.
- Director Resignation: Megan Boston, Chief Financial Officer and Secretary, resigned solely from the Board of Directors effective May 22, 2026. She will continue to serve as CFO and Secretary. Her departure was part of a governance review and was not the result of any dispute.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the company's operations were disclosed in this report. The filing notes that Mr. Friedman will enter into the company's standard indemnification agreement for board members.
Investor Verification Checklist
- Verify the exercise price of the 35,000 options granted to David Friedman based on the May 26, 2026 closing price.
- Confirm the updated Board composition and the specific term end date for the Class III director seat.
- Review the Definitive Proxy Statement on Schedule 14A (filed October 14, 2025) for details on standard non-employee director compensation.
- Confirm that Megan Boston remains in her role as Chief Financial Officer and Secretary.